NASDAQ:ICLR - ICON Stock Price, Price Target & More

$119.08 -2.14 (-1.77 %)

(As of 04/19/2018 04:00 PM ET)

Previous Close$119.08

Today's Range$118.43 - $121.6429

52-Week Range$76.81 - $124.65

Volume212,837 shs

Average Volume316,140 shs

Market Capitalization$6.54 billion

P/E Ratio22.09

Dividend YieldN/A

Beta0.42

About ICON (NASDAQ:ICLR)

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:ICLR

CUSIPN/A

Webwww.iconplc.com

Phone353-1291-2000

Debt

Debt-to-Equity Ratio0.29%

Current Ratio1.95%

Quick Ratio1.95%

Price-To-Earnings

Trailing P/E Ratio22.09

Forward P/E Ratio19.78

P/E Growth1.9

Sales & Book Value

Annual Sales$1.76 billion

Price / Sales3.66

Cash Flow$6.5035 per share

Price / Cash18.31

Book Value$22.02 per share

Price / Book5.41

Profitability

EPS (Most Recent Fiscal Year)$5.39

Net Income$281.48 million

Net Margins16.01%

Return on Equity27.55%

Return on Assets14.86%

Miscellaneous

Employees13,250

Outstanding Shares54,080,000

How to Become a New Pot Stock Millionaire

ICON (NASDAQ:ICLR) Frequently Asked Questions

What is ICON's stock symbol?

ICON trades on the NASDAQ under the ticker symbol "ICLR."

How were ICON's earnings last quarter?

ICON plc (NASDAQ:ICLR) released its earnings results on Thursday, February, 15th. The medical research company reported $1.43 earnings per share for the quarter, topping the consensus estimate of $1.41 by $0.02. The medical research company earned $455.10 million during the quarter, compared to analysts' expectations of $455.66 million. ICON had a return on equity of 27.55% and a net margin of 16.01%. The company's quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.33 earnings per share. View ICON's Earnings History.

When is ICON's next earnings date?

ICON is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for ICON.

What guidance has ICON issued on next quarter's earnings?

ICON issued an update on its FY18 earnings guidance on Thursday, February, 15th. The company provided earnings per share guidance of $5.89-6.09 for the period, compared to the Thomson Reuters consensus estimate of $6.02. The company issued revenue guidance of $2.52-2.64 billion (taking into account ASC 606), compared to the consensus revenue estimate of $1.90 billion.

What price target have analysts set for ICLR?

10 brokerages have issued 1 year price objectives for ICON's stock. Their forecasts range from $114.00 to $133.00. On average, they anticipate ICON's stock price to reach $125.40 in the next year. View Analyst Ratings for ICON.

Who are some of ICON's key competitors?

Some companies that are related to ICON include Exelixis (EXEL), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Viralytics (VRACY), Luna Innovations (LUNA), Anavex Life Sciences (AVXL), Senomyx (SNMX) and Cleveland BioLabs (CBLI).

Who are ICON's key executives?

ICON's management team includes the folowing people:

Dr. Steven A. Cutler, CEO & Director (Age 58)
Mr. Brendan Brennan, Chief Financial Officer (Age 39)
Jonathan Curtain, VP of Corp. Fin. & Investor Relations
Mr. Thomas O'Leary, Chief Information Officer
Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 43)

Has ICON been receiving favorable news coverage?

Headlines about ICLR stock have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ICON earned a coverage optimism score of 0.13 on Accern's scale. They also gave news coverage about the medical research company an impact score of 45.32 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of ICON?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ICON's stock price today?

One share of ICLR stock can currently be purchased for approximately $119.08.

How big of a company is ICON?

ICON has a market capitalization of $6.54 billion and generates $1.76 billion in revenue each year. The medical research company earns $281.48 million in net income (profit) each year or $5.39 on an earnings per share basis. ICON employs 13,250 workers across the globe.

How can I contact ICON?

ICON's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.

MarketBeat Community Rating for ICON (ICLR)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		344 (Vote Outperform)
Underperform Votes:		260 (Vote Underperform)
Total Votes:		604

MarketBeat's community ratings are surveys of what our community members think about ICON and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.

ICON (NASDAQ:ICLR) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

10 Wall Street analysts have issued ratings and price targets for ICON in the last 12 months. Their average twelve-month price target is $125.40, suggesting that the stock has a possible upside of 5.31%. The high price target for ICLR is $133.00 and the low price target for ICLR is $114.00. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.90	2.90	2.90	3.00
Ratings Breakdown:	0 Sell Rating(s) 2 Hold Rating(s) 7 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 7 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 7 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 7 Buy Rating(s) 1 Strong Buy Rating(s)
Consensus Price Target:	$125.40	$125.40	$124.20	$118.25
Price Target Upside:	5.31% upside	10.14% upside	10.03% upside	4.07% upside

ICON (NASDAQ:ICLR) Consensus Price Target History

Price Target History for ICON (NASDAQ:ICLR)

ICON (NASDAQ:ICLR) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/16/2018	Credit Suisse Group	Upgrade	Buy	$131.00	Low
2/15/2018	Mizuho	Reiterated Rating	Neutral -> Neutral	$109.00 -> $114.00	Low
1/22/2018	SunTrust Banks	Reiterated Rating	Buy	$133.00	Low
1/18/2018	Evercore ISI	Initiated Coverage	Outperform -> Outperform	$126.00	High
1/11/2018	KeyCorp	Reiterated Rating	Buy	$130.00	Medium
10/27/2017	Barclays	Boost Price Target	Equal Weight -> Equal Weight	$108.00 -> $120.00	N/A
10/12/2017	Robert W. Baird	Reiterated Rating	Buy	$123.00	N/A
10/9/2017	Jefferies Group	Boost Price Target	Buy	$122.00 -> $132.00	N/A
9/11/2017	Bank of America	Initiated Coverage	Buy -> Buy	$128.00	Low
7/7/2017	Goldman Sachs	Upgrade	Buy -> Conviction-Buy	$117.00	High
10/20/2016	Avondale Partners	Upgrade	Underperform -> Market Perform		N/A

(Data available from 4/19/2016 forward)

ICON (NASDAQ:ICLR) Earnings History and Estimates Chart

Earnings by Quarter for ICON (NASDAQ:ICLR)

ICON (NASDAQ:ICLR) Earnings Estimates

2018 EPS Consensus Estimate: $6.04
2019 EPS Consensus Estimate: $6.73

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	$1.37	$1.44	$1.40
Q2 2018	5	$1.47	$1.53	$1.48
Q3 2018	5	$1.51	$1.58	$1.55
Q4 2018	5	$1.54	$1.65	$1.61
Q1 2019	1	$1.63	$1.63	$1.63
Q2 2019	1	$1.67	$1.67	$1.67
Q3 2019	1	$1.67	$1.67	$1.67
Q4 2019	1	$1.76	$1.76	$1.76

ICON (NASDAQ ICLR) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/3/2018		$1.43					N/A
2/15/2018	Not Specified	$1.41	$1.43	$455.66 million	$455.10 million	View	N/A
10/26/2017	9/30/2017	$1.32	$1.35	$438.09 million	$440.30 million	View	N/A
7/27/2017	6/30/2017	$1.30	$1.31	$430.68 million	$431.00 million	View	N/A
4/27/2017	3/31/2017	$1.27	$1.29	$432.21 million	$432.00 million	View	N/A
2/16/2017	Q416	$1.26	$1.33	$440.78 million	$435.00 million	View	Listen
10/20/2016	Q316	$1.18	$1.19	$420.14 million	$420.20 million	View	Listen
7/26/2016	Q216	$1.14	$1.14	$409.97 million	$411.00 million	View	Listen
4/26/2016	Q116	$1.11	$1.12	$414.35 million	$400.50 million	View	Listen
2/23/2016	Q415	$1.10	$1.11	$409.42 million	$403.00 million	View	Listen
10/27/2015	Q315	$1.01	$1.02	$399.02 million	$394.70 million	View	Listen
7/28/2015	Q215	$0.90	$0.95	$402.15 million	$389.00 million	View	Listen
4/28/2015	Q115	$0.81	$0.90	$391.11 million	$388.00 million	View	N/A
2/25/2015	Q4	$0.76	$0.87	$391.37 million	$390.10 million	View	N/A
10/22/2014	Q314	$0.70	$0.79	$391.12 million	$388.00 million	View	Listen
7/30/2014	Q2	$0.58	$0.64	$376.89 million	$376.00 million	View	Listen
4/30/2014	Q1	$0.50	$0.57	$352.14 million	$350.00 million	View	Listen
2/20/2014	Q413	$0.45	$0.53	$339.86 million	$345.00 million	View	Listen
10/24/2013	Q313	$0.41	$0.45	$332.58 million	$339.80 million	View	Listen
7/25/2013	Q2 2013	$0.38	$0.43	$321.82 million	$334.20 million	View	Listen
4/25/2013	Q1 2013	$0.34	$0.36	$300.81 million	$317.00 million	View	Listen
2/19/2013	Q4 2012	$0.33	$0.34	$291.96 million	$300.00 million	View	Listen
11/1/2012	Q312	$0.27	$0.29	$282.67 million	$286.00 million	View	N/A
7/24/2012		$0.22	$0.21			View	N/A
4/24/2012		$0.15	$0.15			View	N/A
2/16/2012		$0.08	$0.07			View	N/A
10/27/2011		$0.02	$0.02			View	N/A
7/20/2011		$0.22	$0.21			View	N/A
4/21/2011		$0.21	$0.21			View	N/A
2/24/2011		$0.36	$0.36			View	N/A
10/21/2010	Q3 2010	$0.37	$0.33			View	N/A
7/27/2010	Q2 2010	$0.37	$0.38			View	N/A
4/27/2010	Q1 2010	$0.36	$0.37			View	N/A
2/25/2010	Q4 2009	$0.38	$0.40			View	N/A
10/21/2009	Q3 2009	$0.35	$0.40			View	N/A
7/22/2009	Q2 2009	$0.34	$0.38			View	N/A
4/28/2009	Q1 2009	$0.34	$0.35			View	N/A
2/23/2009	Q4 2008	$0.34	$0.35			View	N/A
10/21/2008	Q3 2008	$0.32	$0.35			View	N/A
7/22/2008	Q2 2008	$0.30	$0.31			View	N/A
4/29/2008	Q1 2008	$0.27	$0.28			View	N/A
2/21/2008	Q4 2007	$0.25	$0.27			View	N/A

(Earnings results data provided by Zacks Investment Research)

ICON (NASDAQ:ICLR) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

ICON (NASDAQ ICLR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 44.00%
Institutional Ownership Percentage: 90.59%

Insider Trading History for ICON (NASDAQ:ICLR)

ICON (NASDAQ ICLR) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

ICON (NASDAQ ICLR) News Headlines

Source:

Date	Headline
	'Grace Jones: Bloodlight and Bami' delivers textured profile of music/fashion icon www.latimes.com - April 19 at 5:21 PM
	ICON (ICLR) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 19 at 9:23 AM
	ICON plc (ICLR) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - April 19 at 1:34 AM
	Essential Politics: Remembering a plainspoken political icon, Barbara Bush www.latimes.com - April 18 at 5:29 PM
	Iconix Brand Group (ICON) Sees Hammer Chart Pattern: Time to Buy? www.nasdaq.com - April 18 at 8:36 AM
	ICON (ICLR) Upgraded to Buy at Zacks Investment Research www.americanbankingnews.com - April 18 at 7:46 AM
	BRIEF-ICON Announces Deal With Intel Allowing Integration Of The Intel Pharma Analytics Platform For Clinical Trials www.reuters.com - April 17 at 5:39 PM
	Music icon Beyoncé donates to Dayton-area university www.bizjournals.com - April 17 at 8:55 AM
	ICON plc (ICLR) Expected to Post Quarterly Sales of $617.52 Million www.americanbankingnews.com - April 16 at 2:17 AM
	Mizuho Boosts ICON (ICLR) Price Target to $108.00 www.americanbankingnews.com - April 15 at 2:53 PM
	SunTrust Banks Upgrades ICON (ICLR) to "Buy" www.americanbankingnews.com - April 15 at 9:44 AM
	ICON (ICLR) Given Overweight Rating at KeyCorp www.americanbankingnews.com - April 15 at 9:23 AM
	$1.41 EPS Expected for ICON plc (ICLR) This Quarter www.americanbankingnews.com - April 14 at 9:15 PM
	The Latest: Family fiercely defends Madikizela-Mandela abcnews.go.com - April 14 at 8:44 AM
	William Blair Equities Analysts Cut Earnings Estimates for ICON plc (ICLR) www.americanbankingnews.com - April 13 at 9:29 AM
	A rare glimpse into the family life of 'Star Wars' icon Mark Hamill abcnews.go.com - April 13 at 8:48 AM
	Tamara Houston and ICON MANN are Rewriting the Narratives of Black Men www.forbes.com - April 12 at 5:17 PM
	ICON (ICLR) Upgraded at BidaskClub www.americanbankingnews.com - April 12 at 10:22 AM
	Opinion: Why Winnie Mandela must be celebrated as an African feminist icon www.cnn.com - April 12 at 9:12 AM
	William Blair Weighs in on ICON plc's Q3 2018 Earnings (ICLR) www.americanbankingnews.com - April 12 at 7:18 AM
	GM Is An Icon... But Can It Be More Than That? seekingalpha.com - April 11 at 5:11 PM
	ICON (ICLR) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - April 9 at 9:12 PM
	ICON (ICLR) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - April 9 at 4:05 PM
	EW Nutrition e ICON establecen una asociación estratégica www.prnewswire.com - April 9 at 8:46 AM
	From liberal hero to right-wing icon, Orban's appeal trumps rivals www.reuters.com - April 9 at 8:46 AM
	ICON (ICLR) Earns Buy Rating from Jefferies Group www.americanbankingnews.com - April 8 at 11:23 PM
	Hungarian Vote Surge Threatens Rule of Europe's Populist Icon www.bloomberg.com - April 8 at 5:39 PM
	ICON (ICLR) Downgraded by ValuEngine www.americanbankingnews.com - April 8 at 11:49 AM
	ICON (ICLR) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - April 7 at 2:14 PM
	ICON (ICLR) Cut to Hold at BidaskClub www.americanbankingnews.com - April 6 at 11:07 AM
	Evercore ISI Lowers Icon (ICLR) to Outperform www.americanbankingnews.com - April 3 at 7:49 AM
	Trump Bid to Move 'Hellhole' Embassy Sunk by Architectural Icon www.bloomberg.com - April 1 at 8:39 AM
	Icon (ICLR) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - March 30 at 10:58 AM
	Stephen Reinhardt, circuit court judge, 'progressive icon,' dies at 87 www.foxnews.com - March 30 at 8:43 AM
	Postcard from . . . Ironbridge: saving an industrial icon www.ft.com - March 30 at 8:43 AM
	Rusty Staub, baseball icon, dies at 73 www.usatoday.com - March 30 at 8:43 AM
	Icon Plc Forecasted to Earn Q1 2018 Earnings of $1.38 Per Share (ICLR) www.americanbankingnews.com - March 30 at 6:52 AM
	Icon Plc (ICLR) Expected to Post Quarterly Sales of $622.99 Million www.americanbankingnews.com - March 30 at 1:50 AM
	Icon (ICLR) Downgraded by Zacks Investment Research www.americanbankingnews.com - March 29 at 7:58 PM
	Brokerages Anticipate Icon Plc (ICLR) Will Post Earnings of $1.41 Per Share www.americanbankingnews.com - March 28 at 11:13 PM
	Icon (ICLR) Raised to "Buy" at BidaskClub www.americanbankingnews.com - March 28 at 11:27 AM
	Mike Pence Accused Of Hypocrisy Over Tribute To Civil Rights Icon Linda Brown www.huffingtonpost.com - March 28 at 8:49 AM
	BidaskClub Lowers Icon (ICLR) to Strong Sell www.americanbankingnews.com - March 28 at 12:34 AM
	How This Hong Kong Heiress Became An Unexpected LGBTQ Icon www.huffingtonpost.com - March 27 at 4:59 PM
	ICON's ICX Erases Gains, Remains In Top 20 Cryptocurrencies www.nasdaq.com - March 27 at 8:51 AM
	Dutch soccer icon Gullit switched on by esports www.reuters.com - March 25 at 8:44 AM
	Icon Plc (ICLR) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - March 25 at 1:41 AM
	Kacey Musgraves Dreams Of A Day When 'We Have A Gay Country Music Icon' www.huffingtonpost.com - March 24 at 5:02 PM
	5 Stephen Hawking Quotes to Remember the Iconic Physicist investorplace.com - March 14 at 12:01 PM
	Recent Analysis Shows SMART Global, DBV Technologies S.A, ICON, Adamas Pharmaceuticals, Shenandoah Telecommunications, and Costamare Market Influences — Renewed Outlook, Key Drivers of Growth finance.yahoo.com - March 14 at 9:05 AM